1. Update on Phase 3 tadalafil DMD study: enrollment completed

    Posted on January 13, 20158:48 pm

    CureDuchenne is pleased to share the following update to the Duchenne muscular dystrophy community from Lilly regarding the ongoing Phase 3 trial of tadalafil in boys with Duchenne. Eli Lilly and Company is pleased to announce the completion of enrollment of the Phase 3 trial of tadalafil for patients with Duchenne muscular dystrophy (DMD). The Read more »

  2. Keeping the Promise for our Children with Duchenne

    Posted on January 12, 20158:25 pm

    Today, CureDuchenne announced a $1 million investment in Capricor Therapeutics for a clinical trial to test its CDC (adult) stem cells as a cardiac therapy for Duchenne patients. CureDuchenne’s mission is our name…to cure Duchenne.  Duchenne affects so many parts of the body and cardiac failure is the primary cause of death in this disease.  Read more »

  3. Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy

    Posted on 5:03 pm

    Sarepta Therapeutics released the 168 week data for their exon skipping drug, eteplirsen, this morning.  During a three year period, 7-13 year old boys with Duchenne (the age range of the boys who began the 201 study) would be expected to slow down considerably and many expected to lose ambulation entirely.  After more than three Read more »